516 related articles for article (PubMed ID: 26820213)
21. Hyperprolactinemia: etiology, diagnosis, and management.
Mah PM; Webster J
Semin Reprod Med; 2002 Nov; 20(4):365-74. PubMed ID: 12536359
[TBL] [Abstract][Full Text] [Related]
22. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
[TBL] [Abstract][Full Text] [Related]
23. [Hyperprolactinemia and prolactinemia--investigation and treatment].
Svartberg J; Carlsen SM; Cappelen J; Aanderud S; Johansen ML; Schreiner T; Kollevold T; Bakke S; Bollerslev J
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):494-8. PubMed ID: 11961978
[TBL] [Abstract][Full Text] [Related]
24. Prolactinomas.
Wildemberg LE; Fialho C; Gadelha MR
Presse Med; 2021 Dec; 50(4):104080. PubMed ID: 34687915
[TBL] [Abstract][Full Text] [Related]
25. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
26. Nephrotic-range proteinuria in a patient with a giant prolactinoma.
Heras M; Iglesias P; Fernández-Reyes MJ; Sánchez R; Jiménez MJ; Muñoz H; Tajada P; Duarte J
Am J Kidney Dis; 2008 Jun; 51(6):1025-8. PubMed ID: 18455849
[TBL] [Abstract][Full Text] [Related]
27. Hyperprolactinemia after menopause: Diagnosis and management.
Auriemma RS; Pirchio R; Pivonello R; Colao A
Maturitas; 2021 Sep; 151():36-40. PubMed ID: 34446277
[TBL] [Abstract][Full Text] [Related]
28. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
Hong JW; Lee MK; Kim SH; Lee EJ
Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
[TBL] [Abstract][Full Text] [Related]
29. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
[TBL] [Abstract][Full Text] [Related]
30. Hyperprolactinaemia.
Prabhakar VK; Davis JR
Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):341-53. PubMed ID: 17889620
[TBL] [Abstract][Full Text] [Related]
31. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
32. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
33. [Bromocriptine monotherapy of a prolactinoma causing erectile dysfunction].
López Cubillana P; Hita Rosino E; Asensio Egea L; Rigabert Montiel M; Hita Villaplana G; Server Pastor G; Server Falgás G
Arch Esp Urol; 1997 Jun; 50(5):526-8. PubMed ID: 9382597
[TBL] [Abstract][Full Text] [Related]
34. [Prolactinoma in the male. Physiopathological, clinical, and therapeutic features].
Coppola A; Cuomo MA
Minerva Endocrinol; 1998 Mar; 23(1):7-16. PubMed ID: 9691632
[TBL] [Abstract][Full Text] [Related]
35. Hyperprolactinemia: pathophysiology and therapeutic approach.
Capozzi A; Scambia G; Pontecorvi A; Lello S
Gynecol Endocrinol; 2015 Jul; 31(7):506-10. PubMed ID: 26291795
[TBL] [Abstract][Full Text] [Related]
36. Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
Miki N
Intern Med; 2001 Sep; 40(9):845-6. PubMed ID: 11579939
[No Abstract] [Full Text] [Related]
37. Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1562-7. PubMed ID: 26256063
[TBL] [Abstract][Full Text] [Related]
38. Hyperprolactinaemia and pituitary adenomas in adolescence.
Dissaneevate P; Warne GL
J Pediatr Endocrinol Metab; 1998; 11(4):531-41. PubMed ID: 9777574
[TBL] [Abstract][Full Text] [Related]
39. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
40. Indications for surgery in the treatment of hyperprolactinemia.
Zacur HA
J Reprod Med; 1999 Dec; 44(12 Suppl):1127-31. PubMed ID: 10649823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
